Compare S&P Global Inc (SPGI) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
S&P Global Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? S&P Global Inc trades at $419.2 (market cap $126.56B), while Vertex Pharmaceuticals Incorporated trades at $522.29 (market cap $134.06B). The key difference: S&P Global Inc and Vertex Pharmaceuticals Incorporated are close in size by market cap, and S&P Global Inc pays a 0.9% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| SPGI | VRTX | |
|---|---|---|
Market Cap | $126.56B | $134.06B |
Sector | Financials | Health |
52-Week High | $522.21 | $557.96 |
52-Week Low | $370.42 | $376.62 |
Enterprise Value | $138.05B | $128.18B |
Dividend Yield | 0.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SPGI trades at $429.31, down 3.2% over 24h, with a bullish technical signal and strong fundamentals including a 30.54% net income margin and consistent earnings beats. Recent news highlights strategic acquisitions and a focus on AI-resistant businesses, while analyst consensus remains strongly positive with an 85.7% buy rating.
Outlook is favorable due to high profitability and growth initiatives, but risks include rising debt levels and market sensitivity. The stock offers upside to the $523.20 consensus target, supported by institutional interest and dividend consistency.
Vertex Pharmaceuticals (VRTX) trades at $528.9, down 3.15% on the day, amid a mixed technical and fundamental backdrop. The stock shows a bullish moving average signal but neutral oscillators, with key support at $522. Fundamentally, 2025 revenue reached $12.0B with a strong net income margin of 35%, though recent quarterly EPS results have been mixed. The company recently completed the acquisition of Crinetics Pharmaceuticals, signaling growth ambitions.
The outlook remains positive given analyst consensus favoring a Buy rating (84%) and a $548.78 price target, implying upside. Key opportunities include revenue growth from new drug launches, while risks involve competitive pressures and earnings volatility. The stock's current valuation at a P/E of 30.8 requires sustained execution to justify further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About S&P Global Inc
S&P Global provides data and benchmarks to capital and commodity market participants. In 2021 and excluding IHS Markit, S&P Ratings was over 45% of the firm's revenue and over 55% of the firm's operating income. S&P Ratings is the largest credit rating agency in the world. The firm's other segments include Market Intelligence, Indices, and Platts. Market Intelligence provides desktop tools and other data solutions to investment banks, corporations, and other entities. Indices provides benchmarks for financial markets and is monetized through subscriptions, asset-based fees, and transaction-based royalties. Platts provides benchmarks to commodity markets, principally petroleum.
Read more on SPGI →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
